Use of biologically-based complementary medicine in breast and gynecological cancer patients during systemic therapy

Table 2 Selected therapy characteristics of the total study cohort with univariable analyses of BB-CAM use

CHARACTERISTICS		ALL PATIENTS		BB-CAM				p ¹
				User		Non-user
		Total Count	% of all patients	Count	% of Total	Count	% of Total
		448	100%	332	74.1%	116	25.9%
Therapy line								0.053
Breast-Ca	Neoadjuvant	70	15.6%	58	82.9%	12	17.1%
	Adjuvant	89	19.9%	64	71.9%	25	28.1%
	Metastasis 1^st -line	78	17.4%	45	57.7%	33	42.3%
	Metastasis 2^nd -line	50	11.2%	37	74.0%	13	26.0%
	Metastasis 3^rd -line	20	4.5%	17	85.0%	3	15.0%
	Metastasis ≥4^th -line	53	11.8%	42	79.2%	11	20.8%
	Recurrence 1^st -line	8	1.8%	6	75.0%	2	25.0%
	Recurrence ≥ 2^nd -line	5	1.1%	3	60.0%	2	40.0%
Ovarian-Ca	Neoadjuvant	1	0.2%	1	100.0%	0	0.0%
	Adjuvant	37	8.3%	29	78.4%	8	21.6%
	Recurrent	37	8.3%	30	81.1%	7	18.9%
Therapy
Immune modulation		2	0.4%	2	100.0%	0	0.0%	0.402
Chemotherapy		278	62.1%	220	79.1%	58	20.9%	0.002
Antibodies		196	43.8%	143	73.0%	53	27.0%	0.625
Endocrine		150	33.5%	100	66.7%	50	33.3%	0.011
Bisphosphonates		129	28.8%	87	67.4%	42	32.6%	0.041

¹p values are not adjusted for multiplicity and have to be interpreted to be exploratory